Avacta Group PLC (AVCT) - Total Liabilities
Based on the latest financial reports, Avacta Group PLC (AVCT) has total liabilities worth GBX29.09 Million GBX (≈ $3.54K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Avacta Group PLC - Total Liabilities Trend (2001–2024)
This chart illustrates how Avacta Group PLC's total liabilities have evolved over time, based on quarterly financial data. See Avacta Group PLC (AVCT) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Avacta Group PLC Competitors by Total Liabilities
The table below lists competitors of Avacta Group PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AGS Transact Technologies Limited
NSE:AGSTRA
|
India | Rs-5.35 Billion |
|
SPOBAG AG
F:SBE
|
Germany | €339.85K |
|
Advance Information Marketing Bhd
KLSE:0122
|
Malaysia | RM5.20 Million |
|
GLOW LIFETECH CORP.
F:9DO
|
Germany | €1.48 Million |
|
ARC Funds Ltd
AU:ARC
|
Australia | AU$1.26 Million |
|
Octopus Titan VCT
LSE:OTV2
|
UK | GBX1.26 Million |
|
New Concept Energy Inc
NYSE MKT:GBR
|
USA | $64.00K |
|
The House of Agriculture Spiroy S.A.
AT:SPIR
|
Greece | €29.15 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Avacta Group PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AVCT company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 202.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avacta Group PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avacta Group PLC (2001–2024)
The table below shows the annual total liabilities of Avacta Group PLC from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX38.99 Million ≈ $4.74K |
-24.13% |
| 2023-12-31 | GBX51.39 Million ≈ $6.25K |
-30.76% |
| 2022-12-31 | GBX74.21 Million ≈ $9.03K |
+1183.93% |
| 2021-12-31 | GBX5.78 Million ≈ $703.26 |
+4.46% |
| 2020-12-31 | GBX5.53 Million ≈ $673.21 |
+112.73% |
| 2019-12-31 | GBX2.60 Million ≈ $316.47 |
+27.50% |
| 2018-07-31 | GBX2.04 Million ≈ $248.21 |
+22.60% |
| 2017-07-31 | GBX1.66 Million ≈ $202.46 |
-1.94% |
| 2016-07-31 | GBX1.70 Million ≈ $206.48 |
-25.24% |
| 2015-07-31 | GBX2.27 Million ≈ $276.19 |
+2.62% |
| 2014-07-31 | GBX2.21 Million ≈ $269.14 |
+5.18% |
| 2013-07-31 | GBX2.10 Million ≈ $255.87 |
+37.27% |
| 2012-07-31 | GBX1.53 Million ≈ $186.40 |
+70.41% |
| 2011-07-31 | GBX899.00K ≈ $109.38 |
-28.19% |
| 2010-07-31 | GBX1.25 Million ≈ $152.33 |
+65.17% |
| 2009-07-31 | GBX758.00K ≈ $92.23 |
+175.64% |
| 2008-07-31 | GBX275.00K ≈ $33.46 |
+27.31% |
| 2007-07-31 | GBX216.00K ≈ $26.28 |
+1036.84% |
| 2006-04-30 | GBX19.00K ≈ $2.31 |
-90.21% |
| 2005-04-30 | GBX194.00K ≈ $23.60 |
-44.25% |
| 2004-04-30 | GBX348.00K ≈ $42.34 |
-15.53% |
| 2003-04-30 | GBX412.00K ≈ $50.13 |
-41.81% |
| 2002-04-30 | GBX708.00K ≈ $86.14 |
+23.13% |
| 2001-04-30 | GBX575.00K ≈ $69.96 |
-- |
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more